Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. We note that Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) does have debt on its balance sheet. But is this debt a concern to shareholders?
有人说,波动性,而不是债务,是投资者思考风险的最佳方式,但沃伦·巴菲特曾说过一句名言:“波动性远非风险的代名词。”当我们考虑一家公司的风险时,我们总是喜欢考虑其债务的用途,因为债务过载可能导致破产。我们注意到,Maravai LifeSciences Holdings, Inc.(纳斯达克股票代码:MRVI)的资产负债表上确实有债务。但是这笔债务是股东关心的问题吗?
Why Does Debt Bring Risk?
为什么债务会带来风险?
Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. If things get really bad, the lenders can take control of the business. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. By replacing dilution, though, debt can be an extremely good tool for businesses that need capital to invest in growth at high rates of return. The first step when considering a company's debt levels is to consider its cash and debt together.
债务可以帮助企业,直到企业难以偿还债务,无论是新资本还是自由现金流。如果情况变得非常糟糕,贷款人可以控制业务。但是,更常见(但仍然昂贵)的情况是,公司为了控制债务,必须以低廉的股价稀释股东。但是,通过取代稀释,对于需要资本以高回报率投资增长的企业来说,债务可以成为一个非常好的工具。考虑公司的债务水平的第一步是同时考虑其现金和债务。
What Is Maravai LifeSciences Holdings's Debt?
Maravai LifeSciences Holdings的债务是多少?
As you can see below, Maravai LifeSciences Holdings had US$522.5m of debt, at June 2024, which is about the same as the year before. You can click the chart for greater detail. However, its balance sheet shows it holds US$579.7m in cash, so it actually has US$57.2m net cash.
如下所示,截至2024年6月,Maravai LifeSciences Holdings的债务为5.225亿美元,与前一年大致相同。您可以单击图表以获取更多详细信息。但是,其资产负债表显示其持有5.797亿美元的现金,因此实际上拥有5,720万美元的净现金。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240817/0-7a995a0d593724555475fdd2d7778772-0-b8b06ab397a17721dc9947e6379be4b5.png/big)
A Look At Maravai LifeSciences Holdings' Liabilities
看看 Maravai LifeSciences Holdings 的负债
According to the last reported balance sheet, Maravai LifeSciences Holdings had liabilities of US$68.6m due within 12 months, and liabilities of US$602.6m due beyond 12 months. Offsetting this, it had US$579.7m in cash and US$39.3m in receivables that were due within 12 months. So its liabilities total US$52.2m more than the combination of its cash and short-term receivables.
根据上次报告的资产负债表,Maravai LifeSciences Holdings在12个月内到期的负债为6,860万美元,12个月以后到期的负债为6.026亿美元。与此相抵消的是,它有5.797亿美元的现金和3,930万美元的应收账款将在12个月内到期。因此,其负债总额比其现金和短期应收账款的总和高出5,220万美元。
Of course, Maravai LifeSciences Holdings has a market capitalization of US$2.01b, so these liabilities are probably manageable. However, we do think it is worth keeping an eye on its balance sheet strength, as it may change over time. Despite its noteworthy liabilities, Maravai LifeSciences Holdings boasts net cash, so it's fair to say it does not have a heavy debt load! When analysing debt levels, the balance sheet is the obvious place to start. But it is future earnings, more than anything, that will determine Maravai LifeSciences Holdings's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.
当然,Maravai LifeSciences Holdings的市值为201亿美元,因此这些负债可能是可以控制的。但是,我们确实认为值得关注其资产负债表的实力,因为它可能会随着时间的推移而发生变化。尽管负债值得关注,但Maravai LifeSciences Holdings拥有净现金,因此可以公平地说,它没有沉重的债务负担!在分析债务水平时,资产负债表是显而易见的起点。但是,未来的收益将决定Maravai LifeSciences Holdings未来维持健康资产负债表的能力。因此,如果您专注于未来,可以查看这份显示分析师利润预测的免费报告。
In the last year Maravai LifeSciences Holdings had a loss before interest and tax, and actually shrunk its revenue by 49%, to US$279m. That makes us nervous, to say the least.
去年,Maravai LifeSciences Holdings在利息和税前出现亏损,实际上其收入减少了49万万英镑。279 亿美元。至少可以说,这让我们感到紧张。
So How Risky Is Maravai LifeSciences Holdings?
那么 Maravai LifeSciences Holdings 的风险有多大?
We have no doubt that loss making companies are, in general, riskier than profitable ones. And the fact is that over the last twelve months Maravai LifeSciences Holdings lost money at the earnings before interest and tax (EBIT) line. And over the same period it saw negative free cash outflow of US$17m and booked a US$132m accounting loss. Given it only has net cash of US$57.2m, the company may need to raise more capital if it doesn't reach break-even soon. Summing up, we're a little skeptical of this one, as it seems fairly risky in the absence of free cashflow. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. These risks can be hard to spot. Every company has them, and we've spotted 1 warning sign for Maravai LifeSciences Holdings you should know about.
我们毫不怀疑,总的来说,亏损公司比盈利的公司风险更大。事实是,在过去的十二个月中,Maravai LifeSciences Holdings的利息和税前收益(EBIT)额度出现了亏损。同期,它的自由现金流出为负1700万美元,会计亏损为1.32亿美元。鉴于其净现金仅为5,720万美元,如果不能很快达到收支平衡,该公司可能需要筹集更多资金。总而言之,我们对这个有点怀疑,因为在没有自由现金流的情况下,这似乎相当危险。毫无疑问,我们从资产负债表中学到的关于债务的知识最多。但归根结底,每家公司都可以控制资产负债表之外存在的风险。这些风险可能很难发现。每家公司都有它们,我们发现了一个你应该知道的Maravai LifeSciences Holdings警告信号。
At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.
归根结底,通常最好将注意力集中在没有净负债的公司身上。您可以访问我们的此类公司的特别名单(所有公司都有利润增长记录)。它是免费的。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。